Search

Your search keyword '"Rheumatoid arthritis -- Health aspects"' showing total 44 results
Start Over Descriptor "Rheumatoid arthritis -- Health aspects" Topic rheumatoid factor -- health aspects
44 results on '"Rheumatoid arthritis -- Health aspects"'

2. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-[alpha] therapy

Author

Winthrop, Kevin L., Chang, Eric, Yamashita, Shellie, Iademarco, Michael F., and LoBue, Philip A.

Subjects
Infection -- Health aspects, Rheumatoid arthritis -- Health aspects, Tumors -- Health aspects, Tumor necrosis factor -- Health aspects, Tuberculosis -- Health aspects, Antirheumatic agents -- Health aspects, Corticosteroids -- Health aspects, Rheumatoid factor -- Health aspects, Necrosis -- Health aspects
Abstract

Nontuberculous mycobacteria (NTM) are a large, diverse group of environmental organisms ubiquitous in water and soil (1). They cause a variety of diseases in humans, notably severe, protracted lung disease [...]

Published
2009
Full Text
View/download PDF

4. Biopharmaceuticals: approval trends in 2007: fifteen biopharmaceuticals gained approval in the US or EU in 2007, a though only 9 of them were new approvals

Author

Walsh, Gary

Subjects
Biopharmaceutics -- Health aspects, Anemia -- Health aspects, Rheumatoid factor -- Health aspects, Antiarthritic agents -- Health aspects, Erythropoietin -- Health aspects, Amino acids -- Health aspects, Rheumatoid arthritis -- Health aspects, Growth factors -- Health aspects
Abstract

The year 2007 witnessed the approval of 15 biopharmaceuticals in the United States and/or European Union (EU). The 15 approvals included six erythropoietin (EPO)-based products, three antibodies, and two hormones, [...]

Published
2008

5. COX-2 selective inhibitors and heart health

Author

Simon, Lee S. and White, William B.

Subjects
Coronary artery bypass -- Health aspects, Angiogenesis inhibitors -- Health aspects, Prostaglandins -- Health aspects, Blood pressure -- Health aspects, Nonsteroidal anti-inflammatory drugs -- Health aspects, Analgesics -- Health aspects, Drugs -- Health aspects, Cardiac patients -- Care and treatment, Cardiac patients -- Health aspects, Osteoarthritis -- Risk factors, Osteoarthritis -- Prevention, Osteoarthritis -- Care and treatment, Osteoarthritis -- Health aspects, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Prevention, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects, Rofecoxib -- Health aspects, COX-2 inhibitors -- Health aspects, Hypertension -- Risk factors, Hypertension -- Prevention, Hypertension -- Care and treatment, Hypertension -- Health aspects, Heart attack -- Risk factors, Heart attack -- Prevention, Heart attack -- Care and treatment, Heart attack -- Health aspects, Congestive heart failure -- Risk factors, Congestive heart failure -- Prevention, Congestive heart failure -- Care and treatment, Congestive heart failure -- Health aspects, Antihypertensive drugs -- Health aspects, Pain -- Care and treatment, Pain -- Health aspects, Chemical inhibitors -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Medicare -- Health aspects, Stroke (Disease) -- Risk factors, Stroke (Disease) -- Prevention, Stroke (Disease) -- Care and treatment, Stroke (Disease) -- Health aspects, Health
Published
2005

6. Ultrasounds spot heart disease early in rheumatoid arthritis patients, Mayo Clinic finds

Subjects
Heart diseases -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Health, Rheumatoid factor -- Health aspects, Arthritis -- Health aspects, Cardiovascular diseases -- Health aspects, Physical fitness -- Health aspects, Rheumatoid arthritis -- Health aspects, Health
Abstract

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- ROCHESTER, Minn. - Special echocardiograms show promise for early detection of a potentially deadly complication in rheumatoid [...]

Published
2012

7. Depression and chronic medical illness: why psychiatrists should care

Author

Sachdeva, Shilpa

Subjects
Antiparkinsonian agents -- Health aspects, Antiparkinsonian agents -- Social aspects, Biological response modifiers -- Health aspects, Biological response modifiers -- Social aspects, Cancer patients -- Care and treatment, Cancer patients -- Social aspects, Cancer patients -- Health aspects, Palliative treatment -- Health aspects, Palliative treatment -- Social aspects, Rheumatoid arthritis -- Development and progression, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Health aspects, Rheumatoid arthritis -- Social aspects, Oncology, Experimental -- Development and progression, Oncology, Experimental -- Health aspects, Oncology, Experimental -- Social aspects, Stroke (Disease) -- Development and progression, Stroke (Disease) -- Care and treatment, Stroke (Disease) -- Risk factors, Stroke (Disease) -- Health aspects, Stroke (Disease) -- Social aspects, Psychiatrists -- Social aspects, Psychiatrists -- Health aspects, Antihypertensive drugs -- Health aspects, Antihypertensive drugs -- Social aspects, Congestive heart failure -- Development and progression, Congestive heart failure -- Care and treatment, Congestive heart failure -- Risk factors, Congestive heart failure -- Health aspects, Congestive heart failure -- Social aspects, Hypertension -- Development and progression, Hypertension -- Care and treatment, Hypertension -- Risk factors, Hypertension -- Health aspects, Hypertension -- Social aspects, Cardiac patients -- Care and treatment, Cardiac patients -- Social aspects, Cardiac patients -- Health aspects, Serotonin uptake inhibitors -- Health aspects, Serotonin uptake inhibitors -- Social aspects, Medical care, Cost of -- Health aspects, Medical care, Cost of -- Social aspects, Anxiety -- Development and progression, Anxiety -- Care and treatment, Anxiety -- Risk factors, Anxiety -- Health aspects, Anxiety -- Social aspects, Rheumatoid factor -- Health aspects, Rheumatoid factor -- Social aspects, Cancer -- Research, Cancer -- Development and progression, Cancer -- Health aspects, Cancer -- Social aspects, Pain -- Care and treatment, Pain -- Health aspects, Pain -- Social aspects, Health, Health care industry, Psychology and mental health
Abstract

Issue Depression is one of the most prevalent psychiatric disorders and when co-occurring with medical illnesses likely creates a vicious circle in which each separate ailment makes treatment outcomes worse [...]

Published
2009

8. Eye on Amgen

Author

Barclay, Laurie

Subjects
Rheumatoid factor -- Health aspects, Biotechnology industry -- Product development -- Health aspects, Antirheumatic agents -- Product development -- Health aspects, Cancer -- Care and treatment, Kidney diseases -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Health, Vectibix (Medication) -- Health aspects
Abstract

Amgen is a pioneering biotechnology company in human therapeutics, with more than 25 years of experience applying scientific breakthroughs to the development of new biologic agents. Utilizing advances in recombinant [...]

Published
2011

9. Complementary & alternative medicine for women

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Women -- Health aspects, Antiarthritic agents -- Health aspects, Alternative medicine -- Health aspects, Cancer -- Care and treatment, Cancer -- Health aspects
Abstract

It was bad enough when Jennifer Tilofi* was diagnosed with rheumatoid arthritis six years ago at age 31; but when, after nearly four years of treatment with some pretty toxic […]

Published
2007

10. Event Brief of Q3 2008 Roche Holding AG Sales Conference Call - Final

Subjects
Morgan Stanley -- Product introduction, Roche Holding AG -- Product introduction, Societe Generale S.A. -- Product introduction, Biological products industry -- Product introduction -- Health aspects, Rheumatoid factor -- Health aspects, Diabetes -- Health aspects, Banking industry -- Health aspects -- Product introduction, Erosion -- Health aspects, Customer relations -- Health aspects, Competition (Economics) -- Health aspects, Growth factors -- Health aspects, Pharmaceutical industry -- Product introduction -- Health aspects, Metastasis -- Health aspects, Stomach cancer -- Health aspects, Angiogenesis inhibitors -- Health aspects, Monoclonal antibodies -- Health aspects, Rheumatoid arthritis -- Health aspects, Workflow software, Banking industry, Business, Rituxan (Medication) -- Product introduction -- Health aspects, Tarceva (Medication) -- Product introduction -- Health aspects, Herceptin (Medication) -- Product introduction -- Health aspects, Avastin (Medication) -- Product introduction -- Health aspects
Abstract

PARTICIPANTS . Severin Schwan, Roche Holdings AG, CEO . Bill Burns, Roche Pharmaceuticals, CEO . Juergen Schwiezer, Roche Diagnostics, CEO . Erich Hunziker, Roche Group, CFO . Sachin Jain, Merrill [...]

Published
2008

11. Rheumatoid arthritis drug may increase cancer risk

Subjects
Oncology, Experimental -- Drug therapy, Oncology, Experimental -- Reports, Oncology, Experimental -- Health aspects, Cancer -- Risk factors, Cancer -- Drug therapy, Cancer -- Reports, Cancer -- Health aspects, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Reports, Rheumatoid arthritis -- Health aspects, Methotrexate -- Reports, Methotrexate -- Health aspects, Rheumatoid factor -- Reports, Rheumatoid factor -- Health aspects, Cancer -- Research, Cancer -- Care and treatment, General interest, News, opinion and commentary
Abstract

Sufferers of rheumatoid arthritis who take the antirheumatic drug methotrexate increase their risk of developing certain types of cancer, suggests new research. Rheumatoid arthritis is a chronic inflammatory illness that [...]

Published
2008

12. Fibromyalgia and Hepatitis C: Is There an Association?

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Infection -- Health aspects, Fibromyalgia -- Health aspects, Hepatitis C -- Health aspects, Associations, institutions, etc. -- Health aspects, Societies -- Health aspects, Health
Abstract

Fibromyalgia and Hepatitis C: Is There an Association? ABSTRACT & COMMENTARY Synopsis: Serologic evidence of hepatitis C infection was reported to be more than six times more prevalent in patients [...]

Published
1998

13. Gearing Up for Summer While Living with Moderate to Severe Rheumatoid Arthritis (RA)

Subjects
Rheumatoid arthritis -- Health aspects, Rheumatoid factor -- Health aspects, Arthritis -- Health aspects, News, opinion and commentary, Sports and fitness, Orencia (Medication) -- Health aspects
Abstract

June 5, 2015 Filed under Health & Wellness - Following a long, cold winter that saw heavy snowfall and low temperatures around the country, Americans are finally thawing out and [...]

Published
2015

14. Alder Biopharmaceuticals to receive $15 M milestone payment from Bristol-Myers Squibb for initiation of Phase IIb clinical trial in rheumatoid arthritis of ALD518/BMS-945429 antibody therapeutic against IL-6

Subjects
Bristol-Myers Squibb Co. -- Product development, Biopharmaceutics -- Product development -- Health aspects, Rheumatoid factor -- Health aspects, Clinical trials -- Health aspects, Interleukins -- Product development -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Business, Chemicals, plastics and rubber industries
Abstract

Alder Biopharmaceuticals Inc announced it will receive a $15 M milestone payment from Bristol-Myers Squibb for the initiation of a Phase IIb clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an [...]

Published
2011

15. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6

Subjects
Bristol-Myers Squibb Co. -- Product development, Biopharmaceutics -- Product development -- Health aspects, Rheumatoid factor -- Health aspects, Clinical trials -- Health aspects, Interleukins -- Product development -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Business, News, opinion and commentary
Abstract

BOTHELL, Wash., June 20, 2011 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b [...]

Published
2011

16. Compugen announces positive therapeutic effect of CGEN-15001 in animal model of rheumatoid arthritis

Subjects
Compugen Ltd., Rheumatoid factor -- Health aspects, Biotechnology industry -- Health aspects, Antirheumatic agents -- Health aspects, Rheumatoid arthritis -- Health aspects, Business, Chemicals, plastics and rubber industries
Abstract

Compugen Ltd announced that administration of CGEN-15001 in an animal model of rheumatoid arthritis (RA) dramatically ameliorates the clinical symptoms of the disease. These results, combined with earlier results in [...]

Published
2010

17. Biologic users mycobacterial lung infection

Author

Jancin, Bruce

Subjects
Lung diseases -- Health aspects, Respiratory tract diseases -- Health aspects, Rheumatoid factor -- Health aspects, Antirheumatic agents -- Health aspects, Tumor necrosis factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Health, Health care industry
Abstract

SNOWMASS, COLO. - Rheumatoid arthritis patients on tumor necrosis factor inhibitors are at increased risk for tuberculosis and nontuberculous mycobacterial lung disease, data from Kaiser Permanente of Northern California show. [...]

Published
2012

18. Analyse Therapeutic Clinical Intelligence - Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Health aspects, Biological products -- Market research -- Health aspects, Rheumatoid arthritis -- Health aspects, Marketing research, Business, Business, international
Abstract

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c78644) has announced the addition of 'Therapeutic Clinical Intelligence - Rheumatoid Arthritis' to their offering. The world-wide market for Rheumatoid Arthritis (RA) therapeutics has [...]

Published
2008

19. Rheumatoid arthritis ... Anesthesia ... Hammertoe

Author

Ferrell, Bruce A.

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Rheumatoid factor -- Health aspects, Anesthesia -- Health aspects, Rheumatoid arthritis -- Health aspects, Atherosclerosis -- Health aspects, Health
Abstract

Q I recently read that people with rheumatoid arthritis are at a higher risk for cardiovascular disease than those without arthritis. Why would that be? A Rheumatoid arthritis (RA) is [...]

Published
2010

20. Think infection when lung issues strike in RA

Author

Jancin, Bruce

Subjects
Rheumatoid factor -- Health aspects, Infection -- Health aspects, Rheumatoid arthritis -- Health aspects, Health
Abstract

KEYSTONE, COLO. -- The top diagnostic priorities when a lung problem is detected in a patient with underlying rheumatoid arthritis or another autoimmune disease are to rule out infection and [...]

Published
2010

21. Anti-TNF agents may up skin cancer risk

Author

Napoli, Denise

Subjects
Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects, Oncology, Experimental -- Health aspects, Dermatologic agents -- Health aspects, Rheumatoid factor -- Health aspects, Cancer -- Research, Cancer -- Health aspects, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Health aspects, Cancer -- Care and treatment, Skin -- Care and treatment, Skin -- Health aspects, Health, Health care industry
Abstract

PHILADELPHIA -- Two studies showed an increased risk for non-melanoma skin cancer in patients who take anti-tumor necrosis factor therapies, and should prompt physicians to evaluate the use of these [...]

Published
2009

22. Etanercept: histoplasmosis and invasive fungal infections

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Infection -- Health aspects, Histoplasmosis -- Health aspects, Etanercept -- Health aspects
Abstract

Canada -- The manufacturer of etanercept (Enbrel[R]) has informed healthcare professionals of the risk of invasive fungal infections, including histoplasmosis. Etanercept is indicated for the treatment of rheumatoid arthritis, psoriatic [...]

Published
2009

23. MRSA infections are seen in patients on anti-TNF therapy

Author

Walsh, Nancy

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects, Staphylococcal infections -- Care and treatment, Staphylococcal infections -- Health aspects, Infection -- Care and treatment, Infection -- Health aspects, Staphylococcus aureus -- Health aspects, Tumor necrosis factor -- Health aspects
Abstract

PARIS -- Methicillin-resistant Staphylococcus aureus infections have been reported for the first time in patients with rheumatoid arthritis being treated with tumor necrosis factor inhibitors. In a poster presented at [...]

Published
2008

24. Serious infections with biologics stress need for extra vigilance

Author

Walsh, Nancy

Subjects
Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects, Methotrexate -- Health aspects, Prednisone -- Health aspects, Leflunomide -- Health aspects, Sulfonamides -- Health aspects, Corticosteroids -- Health aspects, Rheumatoid factor -- Health aspects, Infection -- Care and treatment, Infection -- Health aspects, Health, Health care industry
Abstract

LIVERPOOL, ENGLAND -- Serious and even fatal infections continue to occur in patients being treated with tumor necrosis factor-blocking agents and other biologics, emphasizing the need for heightened vigilance during [...]

Published
2008

25. Use of TNF blockers may raise skin cancer risk

Author

Walsh, Nancy

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Health aspects, Antirheumatic agents -- Health aspects, Tumor necrosis factor -- Health aspects, Health, Health care industry, New York University
Abstract

NEW YORK -- The greatest malignancy risk in patients receiving tumor necrosis factor antagonists is skin cancer, Dr. Jeffrey Greenberg said at a rheumatology meeting sponsored by New York University. [...]

Published
2008

26. Heart failure deemed driving force in excess mortality in RA

Author

Jancin, Bruce

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Heart failure -- Health aspects, Mortality
Abstract

SNOWMASS, COLO. -- Heart failure is a major contributor to the excess mortality in patients with rheumatoid arthritis, Dr. Sherine E. Gabriel said at a symposium sponsored by the American [...]

Published
2008

27. Subtle heart failure signs increase RA mortality risk

Author

Mahoney, Diana

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Heart failure -- Health aspects, Mortality
Abstract

BOSTON -- Heart failure appears to be treated less aggressively in people with concomitant rheumatoid arthritis, based on the results of a community-based cohort study. The findings, which were reported [...]

Published
2008

28. Life expectancy no better in RA patients, despite new therapies

Author

Napoli, Denise

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects
Abstract

Rheumatoid arthritis patients have not experienced a decline in mortality, despite dramatically increased life expectancy in the general population and newer, more aggressive arthritis treatments. This stagnation is contributing to [...]

Published
2008

29. High RA disease activity is tied to greater risk of infection

Author

Walsh, Nancy

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Health aspects, Infection -- Risk factors, Infection -- Health aspects, Antirheumatic agents -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects
Abstract

BOSTON -- Increased rheumatoid arthritis disease activity is associated with a greater risk of developing infections, judging from the analysis of data from a large rheumatology database, Dr. Daniel E. [...]

Published
2008

30. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6

Subjects
Bristol-Myers Squibb Co. -- Product development, Biopharmaceutics -- Product development -- Health aspects, Rheumatoid factor -- Health aspects, Clinical trials -- Health aspects, Interleukins -- Product development -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Health
Abstract

Alder Biopharmaceuticals Inc. announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an [...]

Published
2011

31. Reports from Washington University Describe Recent Advances in Rheumatoid Arthritis

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Rheumatoid factor -- Health aspects, Antirheumatic agents -- Health aspects, Infection -- Health aspects, Tumor necrosis factor -- Health aspects, Universities and colleges -- Missouri -- Health aspects, Rheumatoid arthritis -- Health aspects, Biotechnology industry, Pharmaceuticals and cosmetics industries, Washington University
Abstract

Research findings, 'TNF-a antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis,' are discussed in a new report. 'Medications used to treat [...]

Published
2011

32. New rheumatoid arthritis research from University of Paris discussed

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Rheumatoid factor -- Health aspects, Infection -- Health aspects, Universities and colleges -- Health aspects, Rheumatoid arthritis -- Health aspects
Abstract

Current study results from the report, 'Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review,' have been published. According to a study from Paris, France, "To study [...]

Published
2010

33. New 'suicide' molecule halts rheumatoid arthritis

Subjects
Rheumatoid factor -- Health aspects, Antirheumatic agents -- Health aspects, Bones -- Health aspects, Rheumatoid arthritis -- Health aspects, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

A researcher from Northwestern University Feinberg School of Medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that [...]

Published
2010

34. New therapeutic target identified for rheumatoid arthritis

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Antirheumatic agents -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Pharmaceuticals and cosmetics industries
Abstract

Researchers at Hospital for Special Surgery have identified a potential new therapeutic target that could be used to treat inflammatory disorders, such as rheumatoid arthritis (see also Hospital for Special [...]

Published
2008

35. Highlights from the American College of Rheumatology 2008 Annual Meeting

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Cardiac patients -- Health aspects, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Universities and colleges -- Health aspects, Biotechnology industry, Health, Pharmaceuticals and cosmetics industries
Abstract

Rheumatoid Arthritis Patients do Worse After a Heart Attack Following a heart attack, people with rheumatoid arthritis (RA) suffer greater heart-related complications, including an increased risk for dying, when compared [...]

Published
2008

36. Analyse Therapeutic Clinical Intelligence - Rheumatoid Arthritis

Subjects
Marketing research, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Monoclonal antibodies -- Health aspects, Biological products -- Market research, Biological products -- Health aspects, Antirheumatic agents -- Market research, Antirheumatic agents -- Health aspects
Abstract

Research and Markets (http://www.researchandmarkets.com/reports/c78644) has announced the addition of "Therapeutic Clinical Intelligence - Rheumatoid Arthritis" to their offering (see also Biologics). The world-wide market for Rheumatoid Arthritis (RA) therapeutics has [...]

Published
2008

37. Thomas Jefferson University, U.S., researchers report new study findings

Subjects
Gleevec (Medication) -- Health aspects, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Research, Rheumatoid arthritis -- Health aspects, Osteoarthritis -- Research, Osteoarthritis -- Health aspects, Universities and colleges -- Health aspects, Cancer -- Care and treatment, Cancer -- Health aspects
Abstract

Thomas Jefferson University, U.S., researchers report new study findings. This trend article about Thomas Jefferson University, U.S., is an immediate alert from NewsRx to identify developing directions of research. Study [...]

Published
2007

38. Rheumatoid arthritis drug linked to serious infections and cancers

Subjects
Oncology, Experimental -- Drug therapy, Oncology, Experimental -- Health aspects, Cancer -- Drug therapy, Cancer -- Health aspects, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Health aspects, Drugs -- Health aspects, Tumor necrosis factor -- Health aspects, Antirheumatic agents -- Health aspects, Biological products -- Health aspects, Rheumatoid factor -- Health aspects, Infection -- Drug therapy, Infection -- Health aspects, Cancer -- Research, Cancer -- Care and treatment
Abstract

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and [...]

Published
2006

39. Omega-3 Fatty Acids for the Treatment of Rheumatoid Arthritis

Subjects
Cardiovascular diseases -- Research, Cardiovascular diseases -- Risk factors, Cardiovascular diseases -- Drug therapy, Cardiovascular diseases -- Health aspects, Rheumatoid arthritis -- Research, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Health aspects, Antirheumatic agents -- Research, Antirheumatic agents -- Health aspects, Drug therapy, Combination -- Health aspects, Dietary fat -- Health aspects, Cardiac patients -- Drug therapy, Cardiac patients -- Health aspects, Omega-3 fatty acids -- Health aspects, Rheumatoid factor -- Health aspects, Health, Health care industry, Women's issues/gender studies
Abstract

Omega-3 Fatty Acids for the Treatment of Rheumatoid Arthritis By Susan T. Marcolina, MD, FACP Dr. Marcolina is an internist and geriatrician in Issaquah, WA. Dr. Marcolina reports no consultant, [...]

Published
2006

40. Opposite immune responses explain different therapeutic effects in rheumatoid arthritis

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Rheumatoid factor -- Health aspects, Immune response -- Health aspects, Drugs -- Health aspects, Rheumatoid arthritis -- Health aspects, Health, Science and technology, Health aspects
Abstract

Using a humanized mouse model that mimics the effects of human rheumatoid arthritis (RA), researchers have discovered that protein growth factors called cytokines in the immune system have both pro- [...]

Published
2005

41. Opposite immune responses explain different therapeutic effects in rheumatoid arthritis

Subjects
Rheumatoid factor -- Health aspects, Immune response -- Health aspects, Drugs -- Health aspects, Rheumatoid arthritis -- Health aspects, Health, Health aspects
Abstract

Using a humanized mouse model that mimics the effects of human rheumatoid arthritis (RA), researchers have discovered that protein growth factors called cytokines in the immune system have both pro- [...]

Published
2005

42. Opposite immune responses explain different therapeutic effects in rheumatoid arthritis

Subjects
Drugs -- Health aspects, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Immune response -- Health aspects, Growth factors -- Health aspects
Abstract

Using a humanized mouse model that mimics the effects of human rheumatoid arthritis (RA), researchers have discovered that protein growth factors called cytokines in the immune system have both pro- [...]

Published
2005

43. Advances in the Management of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Health aspects, Antirheumatic agents -- Health aspects, Company business management, Family and marriage, Health
Abstract

Advances in the Management of Rheumatoid Arthritis Author: Keith Colburn, MD, Rheumatology Division, Department of Veterans Affairs, Jerry L. Pettis Memorial VA Hospital, Loma Linda, Calif. Editors NoteSince the American [...]

Published
2002

44. According to the Mayo Clinic, there have been reports that patients taking Humira[R] and Remicade[R], two rheumatoid arthritis medications, are at a higher risk for infections

Subjects
Humira (Medication) -- Health aspects, Remicade (Medication) -- Health aspects, Rheumatoid factor -- Health aspects, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Health aspects, Infection -- Risk factors, Infection -- Drug therapy, Infection -- Health aspects, Antiarthritic agents -- Health aspects
Abstract

According to the Mayo Clinic, there have been reports that patients taking Humira[R] and Remicade[R], two rheumatoid arthritis medications, are at a higher risk for infections such as tuberculosis and […]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results